Drug class
Angiogenesis Inhibitors clinical trials
A class of medicines: the studies that test any of its 23 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the angiogenesis inhibitors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- O-(Chloroacetylcarbamoyl)fumagillol
- 2
Studies by the year they started
4,396 studies that test it; most in 2007 (327); 2 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1994 | 1 |
| 1995 | 1 |
| 1996 | 2 |
| 1997 | 9 |
| 1998 | 20 |
| 1999 | 19 |
| 2000 | 45 |
| 2001 | 56 |
| 2002 | 58 |
| 2003 | 61 |
| 2004 | 80 |
| 2005 | 163 |
| 2006 | 294 |
| 2007 | 327 |
| 2008 | 304 |
| 2009 | 287 |
| 2010 | 239 |
| 2011 | 186 |
| 2012 | 198 |
| 2013 | 189 |
| 2014 | 154 |
| 2015 | 167 |
| 2016 | 160 |
| 2017 | 153 |
| 2018 | 128 |
| 2019 | 136 |
| 2020 | 152 |
| 2021 | 140 |
| 2022 | 145 |
| 2023 | 123 |
| 2024 | 142 |
| 2025 | 136 |
| 2026 | 120 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Glioblastoma
- 127
- Melanoma
- 73
Who runs them
Industry 1,020 · Other 3,410
National Cancer Institute (NCI) (307) · M.D. Anderson Cancer Center (140) · Hoffmann-La Roche (110) · Celgene (76) · Pfizer (69) · Memorial Sloan Kettering Cancer Center (66) · Genentech, Inc. (61) · Eli Lilly and Company (59)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 4,430
- Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07756840Written as Bevacizumab
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07830485Written as Lenalidomide
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerRecruitingPhase 3National Cancer Institute (NCI)NCT04181060Written as Bevacizumab
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT06015880Written as Lenalidomide
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaRecruitingPhase 1/2City of Hope Medical CenterNCT05861050Written as Lenalidomide
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingPhase 1/2BeOne MedicinesNCT04973605Written as Pomalidomide
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingPhase 1/2Wake Forest University Health SciencesNCT04822337Written as Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingPhase 2National Cancer Institute (NCI)NCT04981509Written as Bevacizumab
- First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingPhase 2Fudan UniversityNCT07893340Written as Bevacizumab
- VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) StudyNot yet recruitingPhase 2University of MiamiNCT07891182Written as Aflibercept Injection
- Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation RetinopathyRecruitingPhase 3Jaeb Center for Health ResearchNCT05844982Written as Faricimab
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingPhase 2SWOG Cancer Research NetworkNCT04205968Written as Ramucirumab
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingPhase 2University of MiamiNCT05366816Written as Sunitinib
- Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF AgentsRecruitingPhase 4Jaeb Center for Health ResearchNCT07567833Written as Anti-Vascular Endothelial Growth Factor
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT07198074Written as Bevacizumab
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingPhase 1K36 Therapeutics, Inc.NCT05651932Written as Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT06649812Written as Lenalidomide
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Bevacizumab
- PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerRecruitingPhase 2Samsung Medical CenterNCT07884877Written as Immune checkpoint inhibitor-based therapy
- Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNot yet recruitingPhase 1Northwestern UniversityNCT07594548Written as Ramucirumab
See all 4,430 studies that test one of the angiogenesis inhibitors →
Codes
What other systems call Angiogenesis Inhibitors · ClinicalTrials.gg INT008764
- MeSH (NLM) D020533Angiogenesis InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D020533 | Angiogenesis Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.